Kesar Petro Products Fair Value
Kesar Petro Products (KESARPE) average fair value is ₹112.93 across 6 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF), vs a current market price of ₹23.38 (+383.01%), fair value range ₹40.7–₹212.4. For live price and a broader fundamental view, visit KESARPE stock live price.
Fair Value Analysis Export
KESARPE Fair Value vs Current Price — Valuation Summary
KESARPE average fair value, fair value range, price gap and valuation status across 6 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, Discounted Cash Flow (DCF). Explore KESARPE value investing to estimate fundamental worth using multiple valuation models.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
Discounted Cash Flow (DCF)
KESARPE Fair Value Analysis — Data Sources & Coverage
Kesar Petro Products financial data sources, valuation methods applied and sector benchmarks used. Analyse KESARPE shareholder distribution to track promoter, FII and institutional holdings.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
KESARPE vs Chemicals Sector Peers — P/E, P/B & Market Cap
Kesar Petro Products P/E ratio, P/B ratio and market capitalisation vs Chemicals sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Polychem | POLYCHEM | - | 1.8 | ₹86 |
| Kanchi Karpooram | KANCHI | 29.19 | 0.7 | ₹148 |
| Blue Pearl Agriventures | BPAGRI | 2564.0 | 25.33 | ₹1,622 |
| Omkar Pharmachem | OMKARPH | 157.39 | 3.03 | ₹29 |
| Beezaasan Explotech | BEEZAASAN | 20.83 | 1.94 | ₹309 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.